Galactorrhea Due to Psychotropic Drugs

Within the drug safety program in psychiatry AMSP (Arzneimittelsicherheit in der Psychiatrie), severe adverse drug reactions (ADRs) are assessed. Currently 35 psychiatric hospitals and departments are participating in detecting severe ADRs. This paper focuses on prolactin-dependent ADRs such as gynecomastia and galactorrhea due to psychotropic medications. Related to the number of patients surveyed (122,562 from 1993 to 2000), these are rare events (0.03 % or 35 cases). Imputed drugs were mostly antipsychotics, but antidepressants were also imputed in single cases. In the group of antipsychotics, relative frequencies of galactorrhea were highest for amisulpride and risperidone and corresponded to the degree of D2 binding. Galactorrhea assessed as ”severe” was accompanied by distressing symptoms such as pain, tension, enlargement of breasts, or soaked clothing. The AMSP data contribute to the knowledge on endocrine ADRs by the large number of patients examined and help clinicians select the appropriate drug if their patients have been prone to for these ADRs in the past.

References

• 1 Agresti A, Coull B A. Approximate is better than ”exact” for interval estimation of binomial proportions.  Am Stat. 1998;  52 119-126
• 2 Anand V S. Clomipramine induced galactorrhea and amenorrhea.  Br J Psychiatry. 1985;  147 87-88
• 3 Bronzo M R, Stahl S M. Galactorrhea induced by sertraline.  Am J Psychiatry. 1993;  150 1269-1270
• 4 Clopper C J, Pearson E S. The use of confidence of fiducial limits illustrated in the case of the binomial.  Biometrika. 1934;  26 404-413
• 5 David S R, Taylor C C, Kinon B J, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.  Clin Ther. 2000;  22 1085-1096
• 6 Gonzalez E, Minguez L, Sanguino R M. Galactorrhea after paroxetine treatment.  Pharmacopsychiatry. 2000;  33 118
• 7 Grohmann R, Hippius H, Helmchen H, Rüther E, Schmidt L G. The AMÜP study for drug surveillance in psychiatry - a summary of inpatient data.  Pharmacopsychiatry. 2004;  37 Suppl 1 S16-26
• 8 Grohmann R, Engel R, Rüther E, Hippius H. The AMSP Drug Safety Program: Methods and Global Results.  Pharmacopsychiatry. 2004;  37 Suppl 1 S4-11
• 9 Hamner M B, Arana G W. Hyperprolactinaemia in antipsychotic-treated patients: Guidelines for avoidance and management.  CNS Drugs. 1998;  10 209-222
• 10 Kalinowski L B, Hippius H, Klein H E. Biological treatments in psychiatry. New York; Grune and Stratton 1982
• 11 Kleinberg D L, Davis J M, De C oster, Van Baelen B, Brecher M. Prolactin levels and adverse events in patients treated with risperidone.  J Clin Psychopharmacol. 1999;  19 57-61
• 12 Meltzer H Y, Goode D J, Schyve P M, Young M, Fang V S. Effect of clozapine on human serum prolactin levels.  Am J Psychiatry. 1979;  136 1550-1555
• 13 Meltzer H Y, Young M, Metz J. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant.  J Neural Transm. 1979;  45 165-175
• 14 Pollock A, McLaren E H. Serum prolactin concentrations in patients taking neuroleptic drugs.  Clin Endocrinol. 1998;  49 513-516
• 15 Turrone P, Kapur S, Seeman M V, Flint A J. Elevation of prolactin levels by atypical antipsychotics.  Am J Psychiatry. 2002;  159 133-135
• 16 Wieck A, Haddad P. Hyperprolactinemia caused by antipsychotic drugs.  Br Med J. 2002;  324 250-252
• 17 Windgassen K, Wesselmann U, Schulze Monking H. Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology.  Neuropsychobiology. 1996;  33 142-146